Takrolimus: interakcje

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

Avoid alcoholic beverages. (etykieta leku Takrolimus, Interakcje z innymi lekami)

Reserve the combination of amiodarone with other antiarrhythmic therapies that prolong the QTc to patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent. (etykieta leku Amiodaron, Ostrzeżenia i środki ostrożności)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval. (etykieta leku Cyprofloksacyna, Ostrzeżenia i środki ostrożności)

Immunosuppressant/neoplastic: everolimus Co-administration of everolimus and PREZISTA/ritonavir is not recommended. irinotecan Discontinue PREZISTA/ritonavir at least 1 week prior to starting irinotecan therapy. (etykieta leku Darunawir, Interakcje z innymi lekami)

Use with Drugs that Prolong QT Interval and Antiarrhythmic Agents The use of dofetilide in conjunction with other drugs that prolong the QT interval has not been studied and is not recommended. (etykieta leku Dofetylid, Ostrzeżenia)

Dziurawiec może osłabiać działanie tych leków przez przyspieszenie ich rozkładu, co może oznaczać odrzucenie narządu, zakrzepy lub utratę działania. (NCCIH, St. John's Wort)

Concomitant use of COMPLERA with drugs with a known risk to prolong the QTc interval of the electrocardiogram may increase the risk of Torsade de Pointes. (etykieta leku Emtrycytabina + rylpiwiryna + tenofowir, Ostrzeżenia i środki ostrożności)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (etykieta leku Fludrokortyzon, Ostrzeżenia)

Coadministration of other drugs known to prolong the QT interval and which are metabolized via the enzyme CYP3A4 such as erythromycin, pimozide, and quinidine are contraindicated in patients receiving fluconazole. (etykieta leku Flukonazol, Przeciwwskazania)

Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles. (etykieta leku Flunizolid, Środki ostrożności)

Avoid co-administration of CONTEPO with drugs known to prolong the QT interval. (etykieta leku Fosfomycyna, Interakcje z innymi lekami)

Because of foscarnet's tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B, cyclosporine, acyclovir, methotrexate, tacrolimus and intravenous pentamidine (see above) unless the potential benefits outweigh the risks to the patient. (etykieta leku Foskarnet, Interakcje z innymi lekami)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

Avoid grapefruit or grapefruit juice. (etykieta leku Takrolimus, Interakcje z innymi lekami)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)

Avoid the use of FANAPT in combination with any other drugs that prolong the QT interval [see Warnings and Precautions (5.3) ] . (etykieta leku Iloperydon, Interakcje z innymi lekami)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

Immunosuppressants Everolimus Sirolimus Temsirolimus (IV) Not recommended during and 2 weeks after TOLSURA treatment. (etykieta leku Itrakonazol, Interakcje z innymi lekami)

Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etykieta leku Iwabradyna, Ostrzeżenia i środki ostrożności)

About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (etykieta leku Kaptopryl, Ostrzeżenia)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval ( 5.11 , 8.5 ) (etykieta leku Lewofloksacyna, Ostrzeżenia i środki ostrożności)

Avoid use in patients with congenital long QT syndrome, those with hypokalemia, and with other drugs that prolong the QT interval. (etykieta leku Lopinawir + rytonawir, Ostrzeżenia i środki ostrożności)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

…as simvastatin, lovastatin, and CYP3A substrates with narrow therapeutic ranges, such as cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus, due to an increased risk of adverse events. [See Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.3 )] Patients receiving systemic corticosteroids for lifesaving… (etykieta leku Mifepryston, Przeciwwskazania)

Examples diazepam, alprazolam, alcohol Drugs that Prolong QTc Interval Clinical Impact The concomitant use of other drugs which prolong the QTc interval with REMERON/REMERONSolTab, increase the risk of QT prolongation and/or ventricular arrhythmias (e.g., Torsades de Pointes). (etykieta leku Mirtazapina, Interakcje z innymi lekami)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

…methylergonovine • HMG-CoA reductase inhibitors: lovastatin, simvastatin (these drugs can be temporarily discontinued to allow PAXLOVID use [see Table 2 , Drug Interactions (7.3) ] ) • Immunosuppressants: voclosporin • Microsomal triglyceride transfer protein inhibitor: lomitapide • Migraine medications: eletriptan, ubrogepant • Mineralocorticoid receptor antagonists:… (etykieta leku Nirmatrelwir + rytonawir, Przeciwwskazania)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

Avoid coadministration of oxaliplatin injection with medicinal products with a known potential to prolong the QT interval. (etykieta leku Oksaliplatyna, Interakcje z innymi lekami)

Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

Because pimozide prolongs the QT interval of the electrocardiogram it is contraindicated in patients with congenital long QT syndrome, patients with a history of cardiac arrhythmias, patients taking other drugs which prolong the QT interval of the electrocardiogram or patients with known hypokalemia or hypomagnesemia (see also PRECAUTIONS - DRUG INTERACTIONS ). (etykieta leku Pimozyd, Przeciwwskazania)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (etykieta leku Pitolisant, Ostrzeżenia i środki ostrożności)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

Nephrotoxicity and leukoencephalopathy (including deaths) have been reported in clinical efficacy studies in patients with elevated cyclosporine or tacrolimus concentrations. (etykieta leku Pozakonazol, Ostrzeżenia i środki ostrożności)

• Avoid use with other antiarrhythmic agents or drugs that prolong the QT interval. (etykieta leku Propafenon, Ostrzeżenia i środki ostrożności)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

Avoid the concomitant use of drugs known to prolong the QTc interval. (etykieta leku Sertralina, Interakcje z innymi lekami)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

Certain conditions may increase the risk for torsade de pointes or sudden death such as (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval [see Warnings and Precautions ( 5.8 ), Clinical Pharmacology (12.2) ]. (etykieta leku Tetrabenazyna, Interakcje z innymi lekami)

CONTRAINDICATIONS Thioridazine hydrochloride tablet use should be avoided in combination with other drugs that are known to prolong the QTc interval and in patients with congenital long QT syndrome or a history of cardiac arrhythmias. (etykieta leku Tiorydazyna, Przeciwwskazania)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

Therefore, serum concentrations of the calcineurin inhibitor should be monitored during treatment with TYGACIL to avoid drug toxicity. (etykieta leku Tygecyklina, Interakcje z innymi lekami)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (etykieta leku Takrolimus, Ostrzeżenie w ramce)

Avoid concomitant use of VEPPANU with strong CYP3A inhibitors or drugs known to prolong the QTc interval. (etykieta leku Vepdegestrant, Ostrzeżenia i środki ostrożności)

Therefore, ziprasidone should not be given with: • dofetilide, sotalol, quinidine, other Class Ia and III anti-arrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron mesylate, probucol or tacrolimus. (etykieta leku Zyprazydon, Przeciwwskazania)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Concomitant use of agents associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) may increase the risk for hyperkalemia [see Adverse Reactions ( 6.1 )] . (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

However, this is of special importance in patients at risk of or having underlying renal dysfunction and patients taking concomitant nephrotoxic agents such as cyclosporine, tacrolimus, aminoglycosides, vancomycin and non-steroidal anti-inflammatory drugs [See Adverse Reactions (6.2) and Clinical Pharmacology (12.3) ]. (etykieta leku Adefowir, Ostrzeżenia i środki ostrożności)

…electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment in patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other products that lead to QT prolongation, and those with electrolyte disturbances (e.g., hypokalemia, hypocalcemia, or hypomagnesemia). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Effect of P-glycoprotein (P-gp) Inhibitors and Inducers Concomitant taking of P-gp inhibitors (including but not limited to ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir, and amiodarone) with GILOTRIF can increase exposure to afatinib [see Clinical Pharmacology (12.3) ]. (etykieta leku Afatynib, Interakcje z innymi lekami)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Tacrolimus Administration of multiple doses of anidulafungin and a single-dose of tacrolimus to healthy subjects resulted in no significant alteration in the steady state pharmacokinetics of either drug. (etykieta leku Anidulafungina, Interakcje z innymi lekami)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (etykieta leku Arformoterol, Interakcje z innymi lekami)

Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Strong CYP3A Inducers c : Antimycobacterials (e.g., rifampin, rifabutin), anticonvulsants (e.g., phenytoin, carbamazepine and phenobarbital), St John’s wort May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection [see Warnings and Precautions ( 5.10 )]. (etykieta leku Takrolimus, Interakcje z innymi lekami)

Concomitant use of agents associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) may increase the risk for hyperkalemia [see Adverse Reactions ( 6.1 )] . (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (etykieta leku Buprenorfina, Ostrzeżenia i środki ostrożności)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (etykieta leku Buprenorfina + nalokson, Ostrzeżenia i środki ostrożności)

Cannabidiol Drug Interactions When cannabidiol and ASTAGRAF XL are co-administered, closely monitor for an increase in tacrolimus blood levels and for adverse reactions suggestive of tacrolimus toxicity. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

…electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment in patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other products that lead to QT prolongation, and those with electrolyte disturbances (e.g., hypokalemia, hypocalcemia, or hypomagnesemia). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

In another drug-drug interaction study in healthy volunteers, co-administration of LOKELMA 15 g decreased the systemic exposures of tacrolimus (Figure 2), likely due to LOKELMA’s action on elevating gastric pH. (etykieta leku Cyklokrzemian sodowo-cyrkonowy, Interakcje z innymi lekami)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

QT Interval Prolongation and V entricular A rr h ythmia Decreases in serum calcium can also prolong the QT interval, potentially resulting in ventricular arrhythmia. (etykieta leku Cynakalcet, Ostrzeżenia i środki ostrożności)

Avoid use of Citalopram Capsules in patients with congenital long QT syndrome, bradycardia, hypokalemia or hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure and patients taking other drugs that prolong the QTc interval. (etykieta leku Cytalopram, Ostrzeżenia i środki ostrożności)

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and… (etykieta leku Takrolimus, Interakcje z innymi lekami)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Tacrolimus Clinical Impact: Potentially increased exposure of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19 . (etykieta leku Dekslanzoprazol, Interakcje z innymi lekami)

Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (etykieta leku Denosumab, Ostrzeżenia i środki ostrożności)

Carefully monitor cardiac rhythm when administering SUPRANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (etykieta leku Desfluran, Ostrzeżenia i środki ostrożności)

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and… (etykieta leku Takrolimus, Interakcje z innymi lekami)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

…electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment in patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other products that lead to QT prolongation, and those with electrolyte disturbances (e.g., hypokalemia, hypocalcemia, or hypomagnesemia). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and… (etykieta leku Takrolimus, Interakcje z innymi lekami)

Strong CYP3A Inducers c : Antimycobacterials (e.g., rifampin, rifabutin), anticonvulsants (e.g., phenytoin, carbamazepine and phenobarbital), St John’s wort May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection [see Warnings and Precautions ( 5.10 )]. (etykieta leku Takrolimus, Interakcje z innymi lekami)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

…cardiac disease, 3) treatment with Class I and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval (see PRECAUTIONS, Drug Interactions ), and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs… (etykieta leku Droperydol, Ostrzeżenia)

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and… (etykieta leku Takrolimus, Interakcje z innymi lekami)

…electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment in patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other products that lead to QT prolongation, and those with electrolyte disturbances (e.g., hypokalemia, hypocalcemia, or hypomagnesemia). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Strong CYP3A Inhibitors c : Protease inhibitors (e.g., nelfinavir, telaprevir, boceprevir, ritonavir), azole antifungals (e.g., voriconazole, posaconazole, itraconazole, ketoconazole), antibiotics (e.g., clarithromycin, troleandomycin, chloramphenicol), nefazodone, letermovir, Schisandra sphenanthera extracts May increase tacrolimus whole blood trough concentrations… (etykieta leku Takrolimus, Interakcje z innymi lekami)

When used concomitantly with digoxin or other substrates of P-gp with a narrow therapeutic index such as cyclosporine, everolimus, sirolimus and tacrolimus, caution and appropriate monitoring should be used [see Clinical Pharmacology (12.3) ] . (etykieta leku Eleksakaftor + tezakaftor + iwakaftor, Interakcje z innymi lekami)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. (etykieta leku Erybulina, Ostrzeżenia i środki ostrożności)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

…electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment in patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other products that lead to QT prolongation, and those with electrolyte disturbances (e.g., hypokalemia, hypocalcemia, or hypomagnesemia). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and… (etykieta leku Takrolimus, Interakcje z innymi lekami)

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and… (etykieta leku Takrolimus, Interakcje z innymi lekami)

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and… (etykieta leku Takrolimus, Interakcje z innymi lekami)

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and… (etykieta leku Takrolimus, Interakcje z innymi lekami)

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and… (etykieta leku Takrolimus, Interakcje z innymi lekami)

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and… (etykieta leku Takrolimus, Interakcje z innymi lekami)

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and… (etykieta leku Takrolimus, Interakcje z innymi lekami)

Strong CYP3A Inducers c : Antimycobacterials (e.g., rifampin, rifabutin), anticonvulsants (e.g., phenytoin, carbamazepine and phenobarbital), St John’s wort May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection [see Warnings and Precautions ( 5.10 )]. (etykieta leku Takrolimus, Interakcje z innymi lekami)

Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Tacrolimus Clinical Impact: Potentially increased exposure of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19. (etykieta leku Ezomeprazol, Interakcje z innymi lekami)

Strong CYP3A Inducers c : Antimycobacterials (e.g., rifampin, rifabutin), anticonvulsants (e.g., phenytoin, carbamazepine and phenobarbital), St John’s wort May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection [see Warnings and Precautions ( 5.10 )]. (etykieta leku Takrolimus, Interakcje z innymi lekami)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Strong CYP3A Inducers c : Antimycobacterials (e.g., rifampin, rifabutin), anticonvulsants (e.g., phenytoin, carbamazepine and phenobarbital), St John’s wort May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection [see Warnings and Precautions ( 5.10 )]. (etykieta leku Takrolimus, Interakcje z innymi lekami)

Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including fenofibrate, there is a risk that an interaction will lead to deterioration of renal… (etykieta leku Fenofibrat, Interakcje z innymi lekami)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

…prolonged QT interval, 3) treatment with Class 1 and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs (e.g., diuretics) that may cause electrolyte… (etykieta leku Fentanyl, Ostrzeżenia i środki ostrożności)

Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

…electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment in patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other products that lead to QT prolongation, and those with electrolyte disturbances (e.g., hypokalemia, hypocalcemia, or hypomagnesemia). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Use with caution in combination with other drugs that prolong the QT interval ( 4.2 , 5.11 , 7.7 , 7.8 ) 7.1 Monoamine Oxidase Inhibitors (MAOI) [See Dosage and Administration ( 2.9 , 2.10 ), Contraindications ( 4.1 ), and Warnings and Precautions ( 5.2 )] . (etykieta leku Fluoksetyna, Interakcje z innymi lekami)

…Antidepressants, QTc Prolonging Drugs Formoterol, as with other beta 2 -agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. (etykieta leku Formoterol, Interakcje z innymi lekami)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and… (etykieta leku Takrolimus, Interakcje z innymi lekami)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Strong CYP3A Inducers c : Antimycobacterials (e.g., rifampin, rifabutin), anticonvulsants (e.g., phenytoin, carbamazepine and phenobarbital), St John’s wort May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection [see Warnings and Precautions ( 5.10 )]. (etykieta leku Takrolimus, Interakcje z innymi lekami)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (etykieta leku Goserelina, Ostrzeżenia i środki ostrożności)

Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

This observation should be considered in making clinical decisions regarding patient monitoring when prescribing HYSINGLA ER in patients with congestive heart failure, bradyarrhythmias, electrolyte abnormalities, or who are taking medications that are known to prolong the QTc interval. (etykieta leku Hydrokodon, Ostrzeżenia i środki ostrożności)

…electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment in patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other products that lead to QT prolongation, and those with electrolyte disturbances (e.g., hypokalemia, hypocalcemia, or hypomagnesemia). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Monitor QT interval when administering FORANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (etykieta leku Izofluran, Ostrzeżenia i środki ostrożności)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Cannabidiol Drug Interactions When cannabidiol and ASTAGRAF XL are co-administered, closely monitor for an increase in tacrolimus blood levels and for adverse reactions suggestive of tacrolimus toxicity. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Caspofungin May decrease tacrolimus whole blood trough concentrations. (etykieta leku Takrolimus, Interakcje z innymi lekami)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Strong CYP3A Inducers c : Antimycobacterials (e.g., rifampin, rifabutin), anticonvulsants (e.g., phenytoin, carbamazepine and phenobarbital), St John’s wort May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection [see Warnings and Precautions ( 5.10 )]. (etykieta leku Takrolimus, Interakcje z innymi lekami)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and… (etykieta leku Takrolimus, Interakcje z innymi lekami)

…droperidol, pimozide), specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin), Class 1A antiarrhythmic medications (e.g., quinidine, procainamide) or Class III antiarrhythmics (e.g., amiodarone, sotalol), and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus). (etykieta leku Klozapina, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Frequent PT/INR determinations are advisable until it has been definitely determined that the PT/INR has stabilized Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route… (etykieta leku Kwas fenofibrowy, Interakcje z innymi lekami)

Strong CYP3A Inducers c : Antimycobacterials (e.g., rifampin, rifabutin), anticonvulsants (e.g., phenytoin, carbamazepine and phenobarbital), St John’s wort May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection [see Warnings and Precautions ( 5.10 )]. (etykieta leku Takrolimus, Interakcje z innymi lekami)

…Class 1A antiarrythmics (e.g., quinidine, procainamide) or Class III antiarrythmics (e.g., amiodarone, sotalol), antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval (e.g., pentamidine, levomethadyl acetate, methadone). (etykieta leku Kwetiapina, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Strong CYP3A Inducers c : Antimycobacterials (e.g., rifampin, rifabutin), anticonvulsants (e.g., phenytoin, carbamazepine and phenobarbital), St John’s wort May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection [see Warnings and Precautions ( 5.10 )]. (etykieta leku Takrolimus, Interakcje z innymi lekami)

Strong CYP3A Inducers c : Antimycobacterials (e.g., rifampin, rifabutin), anticonvulsants (e.g., phenytoin, carbamazepine and phenobarbital), St John’s wort May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection [see Warnings and Precautions ( 5.10 )]. (etykieta leku Takrolimus, Interakcje z innymi lekami)

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and… (etykieta leku Takrolimus, Interakcje z innymi lekami)

TYKERB may prolong the QT interval in some patients. (etykieta leku Lapatynib, Ostrzeżenia i środki ostrożności)

HBV reactivation has also been reported in patients receiving certain immunosuppressants or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV direct-acting antivirals may be increased in these patients. (etykieta leku Ledipaswir + sofosbuwir, Ostrzeżenia i środki ostrożności)

Other drugs, such as: Magnesium and aluminum hydroxide antacids Metoclopramide May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and Precautions ( 5.7 , 5.10 , 5.11 )]. (etykieta leku Takrolimus, Interakcje z innymi lekami)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (etykieta leku Leuprorelina, Ostrzeżenia i środki ostrożności)

Strong CYP3A Inducers c : Antimycobacterials (e.g., rifampin, rifabutin), anticonvulsants (e.g., phenytoin, carbamazepine and phenobarbital), St John’s wort May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection [see Warnings and Precautions ( 5.10 )]. (etykieta leku Takrolimus, Interakcje z innymi lekami)

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and… (etykieta leku Takrolimus, Interakcje z innymi lekami)

…electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment in patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other products that lead to QT prolongation, and those with electrolyte disturbances (e.g., hypokalemia, hypocalcemia, or hypomagnesemia). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

…electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment in patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other products that lead to QT prolongation, and those with electrolyte disturbances (e.g., hypokalemia, hypocalcemia, or hypomagnesemia). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (etykieta leku Meflochina, Interakcje z innymi lekami)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

…electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment in patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other products that lead to QT prolongation, and those with electrolyte disturbances (e.g., hypokalemia, hypocalcemia, or hypomagnesemia). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Strong CYP3A Inducers c : Antimycobacterials (e.g., rifampin, rifabutin), anticonvulsants (e.g., phenytoin, carbamazepine and phenobarbital), St John’s wort May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection [see Warnings and Precautions ( 5.10 )]. (etykieta leku Takrolimus, Interakcje z innymi lekami)

Other drugs, such as: Magnesium and aluminum hydroxide antacids Metoclopramide May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and Precautions ( 5.7 , 5.10 , 5.11 )]. (etykieta leku Takrolimus, Interakcje z innymi lekami)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Drugs that Prolong the QT Interval QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. (etykieta leku Metronidazol, Interakcje z innymi lekami)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Mild or Moderate CYP3A Inducers Methylprednisolone, prednisone May decrease tacrolimus whole blood trough concentrations. (etykieta leku Takrolimus, Interakcje z innymi lekami)

…grapefruit juice is a strong CYP3A inhibitor; low dose or single strength grapefruit juice is a moderate CYP3A inhibitor. c Strong CYP3A inhibitor/inducer, based on reported effect on exposures to tacrolimus along with supporting in vitro CYP3A inhibitor/inducer data, or based on drug-drug interaction studies with midazolam (sensitive CYP3A probe substrate). (etykieta leku Takrolimus, Interakcje z innymi lekami)

Strong CYP3A Inhibitors c : Protease inhibitors (e.g., nelfinavir, telaprevir, boceprevir, ritonavir), azole antifungals (e.g., voriconazole, posaconazole, itraconazole, ketoconazole), antibiotics (e.g., clarithromycin, troleandomycin, chloramphenicol), nefazodone, letermovir, Schisandra sphenanthera extracts May increase tacrolimus whole blood trough concentrations… (etykieta leku Takrolimus, Interakcje z innymi lekami)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Pharmacokinetic studies between moxifloxacin and other drugs that prolong the QT interval such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants have not been performed. (etykieta leku Moksyfloksacyna, Ostrzeżenia i środki ostrożności)

Effect of Micafungin in Sodium Chloride Injection on Other Drugs CYP3A4 Substrates There was no effect of single or multiple doses of micafungin for injection on cyclosporine, tacrolimus, prednisolone, voriconazole and fluconazole pharmacokinetics. (etykieta leku Mykafungina, Interakcje z innymi lekami)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Tacrolimus Clinical Impact : Concomitant use of esomeprazole magnesium and tacrolimus may increase exposure of tacrolimus Intervention : During concomitant use of naproxen and esomeprazole magnesium delayed-release tablets and tacrolimus, monitor tacrolimus whole blood concentrations. (etykieta leku Naproksen + ezomeprazol, Interakcje z innymi lekami)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and… (etykieta leku Takrolimus, Interakcje z innymi lekami)

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and… (etykieta leku Takrolimus, Interakcje z innymi lekami)

Calcium-channel blocking agents may increase tacrolimus blood concentrations and require dosage reduction of ASTAGRAF XL [see Drug Interactions ( 7.2 )] . (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and… (etykieta leku Takrolimus, Interakcje z innymi lekami)

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and… (etykieta leku Takrolimus, Interakcje z innymi lekami)

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and… (etykieta leku Takrolimus, Interakcje z innymi lekami)

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and… (etykieta leku Takrolimus, Interakcje z innymi lekami)

Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Use olanzapine and fluoxetine capsules with caution in combination with other drugs that prolong the QT interval ( 4.2 , 5.20 , 7.7 , 7.8 ) 7.1 Monoamine Oxidase Inhibitors (MAOIs) [See Dosage and Administration ( 2.4 , 2.5 ), Contraindications ( 4.1 ), and Warnings and Precautions ( 5.6 )] . (etykieta leku Olanzapina + fluoksetyna, Interakcje z innymi lekami)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

…or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and Precautions… (etykieta leku Takrolimus, Interakcje z innymi lekami)

…or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and Precautions… (etykieta leku Takrolimus, Interakcje z innymi lekami)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

…combination with other drugs that are known to prolong QTc including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval. (etykieta leku Paliperydon, Ostrzeżenia i środki ostrożności)

Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etykieta leku Pasyreotyd, Interakcje z innymi lekami)

Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (etykieta leku Penicylamina, Ostrzeżenia)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Mild or Moderate CYP3A Inducers Methylprednisolone, prednisone May decrease tacrolimus whole blood trough concentrations. (etykieta leku Takrolimus, Interakcje z innymi lekami)

Strong CYP3A Inducers c : Antimycobacterials (e.g., rifampin, rifabutin), anticonvulsants (e.g., phenytoin, carbamazepine and phenobarbital), St John’s wort May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection [see Warnings and Precautions ( 5.10 )]. (etykieta leku Takrolimus, Interakcje z innymi lekami)

…electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment in patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other products that lead to QT prolongation, and those with electrolyte disturbances (e.g., hypokalemia, hypocalcemia, or hypomagnesemia). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between Primaquine phosphate Tablets and other drugs that effect cardiac conduction is unknown. (etykieta leku Prymachina, Interakcje z innymi lekami)

Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Tacrolimus Clinical Impact: Potentially increased exposure of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19 . (etykieta leku Rabeprazol, Interakcje z innymi lekami)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

QT Interval Prolongation The overall analysis of ECG data in pediatric patients indicates that the concomitant use of Rocuronium Bromide Injection with general anesthetic agents can prolong the QTc interval [see Clinical Studies ( 14.3 )]. (etykieta leku Rokuronium, Ostrzeżenia i środki ostrożności)

Strong CYP3A Inducers c : Antimycobacterials (e.g., rifampin, rifabutin), anticonvulsants (e.g., phenytoin, carbamazepine and phenobarbital), St John’s wort May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection [see Warnings and Precautions ( 5.10 )]. (etykieta leku Takrolimus, Interakcje z innymi lekami)

Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

In healthy subjects, 75 mg once daily and 300 mg once daily (3 times and 12 times the dose in EDURANT) have been shown to prolong the QTc interval of the electrocardiogram. (etykieta leku Rylpiwiryna, Ostrzeżenia i środki ostrożności)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

For oral medication where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy (e.g., cyclosporine, tacrolimus, levothyroxine), consider separation of the timing of the administration of the two drugs [see Clinical Pharmacology (12.3) ] . (etykieta leku Sewelamer, Interakcje z innymi lekami)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (etykieta leku Sewofluran, Ostrzeżenia)

HBV reactivation has also been reported in patients receiving certain immunosuppressant or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV direct-acting antivirals may be increased in these patients. (etykieta leku Sofosbuwir + welpataswir, Ostrzeżenia i środki ostrożności)

Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etykieta leku Sorafenib, Ostrzeżenia i środki ostrożności)

…electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment in patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other products that lead to QT prolongation, and those with electrolyte disturbances (e.g., hypokalemia, hypocalcemia, or hypomagnesemia). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etykieta leku Sunitynib, Interakcje z innymi lekami)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etykieta leku Temsyrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Strong CYP3A Inducers c : Antimycobacterials (e.g., rifampin, rifabutin), anticonvulsants (e.g., phenytoin, carbamazepine and phenobarbital), St John’s wort May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection [see Warnings and Precautions ( 5.10 )]. (etykieta leku Takrolimus, Interakcje z innymi lekami)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (etykieta leku Tryptorelina, Ostrzeżenia i środki ostrożności)

Cyclosporine, Tacrolimus: There are several case reports suggesting that metronidazole has the potential to increase the levels of cyclosporine and tacrolimus. (etykieta leku Tynidazol, Interakcje z innymi lekami)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

…like other beta 2 -agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval or within 2 weeks of discontinuation of such agents, because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. (etykieta leku Umeklidynium + wilanterol, Interakcje z innymi lekami)

Other drugs associated with myelosuppression or nephrotoxicity (e.g., adriamycin, dapsone, doxorubicin, flucytosine, hydroxyurea, pentamidine, tacrolimus, trimethoprim/ sulfamethoxazole, vinblastine, vincristine, and zidovudine) Unknown Because of potential for higher toxicity, coadministration with valganciclovir hydrochloride should be considered only if the… (etykieta leku Walgancyklowir, Interakcje z innymi lekami)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etykieta leku Takrolimus, Ostrzeżenia i środki ostrożności)

Strong CYP3A Inducers c : Antimycobacterials (e.g., rifampin, rifabutin), anticonvulsants (e.g., phenytoin, carbamazepine and phenobarbital), St John’s wort May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection [see Warnings and Precautions ( 5.10 )]. (etykieta leku Takrolimus, Interakcje z innymi lekami)

Other drugs, such as: Magnesium and aluminum hydroxide antacids Metoclopramide May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and Precautions ( 5.7 , 5.10 , 5.11 )]. (etykieta leku Takrolimus, Interakcje z innymi lekami)

Reduce ASTAGRAF XL dose (for voriconazole and posaconazole, give one-third of the original dose) and adjust dose based on tacrolimus whole blood trough concentrations [see Dosage and Administration ( 2.3 , 2.4 ) and Clinical Pharmacology ( 12.3 )]. (etykieta leku Takrolimus, Interakcje z innymi lekami)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etykieta leku Zasadowy cytrynian bizmutu + metronidazol + tetracyklina, Ostrzeżenia i środki ostrożności)

Strong CYP3A Inducers c : Antimycobacterials (e.g., rifampin, rifabutin), anticonvulsants (e.g., phenytoin, carbamazepine and phenobarbital), St John’s wort May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection [see Warnings and Precautions ( 5.10 )]. (etykieta leku Takrolimus, Interakcje z innymi lekami)

Thirty-four patients were treated with corticosteroids and one patient was treated with a non-steroidal immunosuppressant. (etykieta leku Aksytynib, Ostrzeżenia i środki ostrożności)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persists despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (etykieta leku Atorwastatyna, Ostrzeżenia i środki ostrożności)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy without significant inflammation; and improvement with immunosuppressive agents. (etykieta leku Ezetymib + symwastatyna, Ostrzeżenia i środki ostrożności)

IMNM is characterized by proximal muscle weakness and elevated serum CK, which persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody, muscle biopsy showing necrotizing myopathy, and improvement with immunosuppressive agents. (etykieta leku Fluwastatyna, Ostrzeżenia i środki ostrożności)

IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (etykieta leku Lowastatyna, Ostrzeżenia)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (etykieta leku Pitawastatyna, Ostrzeżenia i środki ostrożności)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (etykieta leku Prawastatyna, Ostrzeżenia i środki ostrożności)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (etykieta leku Propylotiouracyl, Ostrzeżenia)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (etykieta leku Rozuwastatyna, Ostrzeżenia i środki ostrożności)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy without significant inflammation; and improvement with immunosuppressive agents. (etykieta leku Symwastatyna, Ostrzeżenia i środki ostrożności)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (etykieta leku Tiamazol, Ostrzeżenia)